Galena Biopharma Inc (NASDAQ:GALE) has announced that it would be presenting at the European Society for Medical Oncology Congress, due to be held in Copenhagen, Denmark. The company stated that it would make use of the opportunity to present interim safety data from a phase-2b trial of NeuVax. The study had a patient population of 300 and was aimed at combining the drug with trastuzumab, in order to prevent the recurrence of breast cancer.

In a press release, GALE announced that it would also be delivering a poster presentation, which highlights that the combination of the two drugs is well tolerated and the cardiac effects of trastuzumab remain unchanged. Bijan Nejadnik, the CMO of the company, claimed that the popularity of combinational therapies is growing, since they yield the greatest clinical benefits. He pointed out that the study continues to enroll patients and would do so, until the end of the year. Mr. Nejadnik also confirmed that they would be able to provide efficacy and immunologic data, 12-months after the follow-up.

Earlier, the company had also attended the International Cancer Immunotherapy Conference, in New York. GALE presented the data from phase 1/2a clinical trials of GALE-301, at the conference. The management stated that the presentation had been focused towards the association of folate binding protein expression and clinical outcomes. GALE-301 was being studied in combination with GM-CSF, as part of the trials, targeted at the prevention of cancer recurrence, for ovarian and endometrial cancer patients.

As per the results from the trial, disease free survival had been observed in patients with low FBP expression levels, but was not successful in high FBP expression levels. Mr. Nejadnik had commented on the results, claiming that this was quite informative, given that very little is known about the effects of FBP expression levels and FBP directed therapies. He claimed that the findings warranted further study of the drugs, so as to help with the design and identification of the patient population for the next trial phase.

Galena Biopharma Inc (NASDAQ:GALE) declined by 3.11%, during the October 10 trading session, to close at $0.303 per share.